Pharmaceutical Executive Digest Europe - January 21, 2009 - (Page 3) News Big Pharma speculates on industry’s next 10 years AstraZeneca (AZ), Eli Lilly, Pfizer and Novartis are among the companies gathering in London next month to assess the prospects for pharma market growth in the next 10 years. The Economist’s 15th Annual Pharma Summit, taking place on 12 February, will feature keynote speeches from AZ’s UK chair Chris Brinsmead, Lilly UK’s Andrew Hotchkiss, Shire CEO Angus Russell and head of the Association of the British Pharmaceutical Industry, Richard Barker. The summit’s debates and presentations promise to offer a macro economic outlook of the next few years, a discussion on the less heralded markets with long-term growth prospects, and an assessment of the next low-cost destinations for R&D investment. Further details and registration information are available at www.thepharmasummit.com For more on these news stories and all the latest breaking pharma news, look at our website www.pharmexeceurope.com Uzbekistan set for rapid pharma growth BMI’s Drug Expenditure Forecast Model has revealed that spending on pharmaceuticals in Uzbekistan will increase significantly over next five years, from US$258mn in 2007 to US$645mn in 2012. This translates to compound annual growth rate (CAGR) of 20.1%, which makes the country one of the fastest growing pharmaceutical markets. Foreign firms currently dominate Uzbekistan’s pharmaceutical market, with all of the top ten ranking manufacturers, according to sales, based abroad. Kenya’s pharma fears Regulatory environment, procurement and supply chain difficulties, and a widespread counterfeiting market are affecting operations of pharmaceutical firms in Kenya, according to a recently released report. The report states: “Kenya has slipped by one position to position 15 in a survey covering Africa and the Middle East of countries offering conducive environments for pharmaceutical businesses. “Additionally, inflationary pressures and rising costs of imported raw materials for pharmaceutical production have in recent years resulted in closure of manufacturing facilities by some foreign companies.” UK-based pharmaceutical giant GlaxoSmithKline (GSK) has also highlighted difficulties faced by pharmaceutical manufacturers in Kenya, although it plans to remain in the country. Last August, GSK launched cervical cancer vaccine Cervirax in Kenya, which became one of the first countries in Africa to have access the drug. Cervirax recently received prequalification approvals from the World Health Organisation (WHO), which means that GSK can now arrange special purchase agreements with major buyers of drugs through a tiered-pricing concession programme. First biologic psoriasis treatment approved for use in children The European Commission (EC) has granted marketing authorisation of the use of Wyeth’s Enbrel for children and adolescents with chronic severe plaque psoriasis. Enbrel (etanercept) is the first biologic licensed for treatment of the condition in this age group. Across Europe, 5.1 million people are estimated to have psoriasis; approximately 80% of these have plaque psoriasis, characterised by red, scaly patches on the skin. Somos/Veer/Getty Images 4 FROM THE EDITOR Obama and Pharma! 5 DEALS The top 15 pharma deals of 2008 8 HEALTH IT Obama and Biopharma! 11 BioFutures Forging a true industry– academia partnership http://www.pharmexeceurope.com http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/uzbekistan_pharmaceuticals_healthcare_report_q4_2008_1.html http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/uzbekistan_pharmaceuticals_healthcare_report_q4_2008_1.html http://www.thepharmasummit.com http://www.companiesandmarkets.com/Summary-Market-Report/Kenya-Pharmaceuticals-and-Healthcare-Report-Q4-2008-58403.asp http://www.companiesandmarkets.com/Summary-Market-Report/Kenya-Pharmaceuticals-and-Healthcare-Report-Q4-2008-58403.asp
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.